We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
Merck (MRK - Free Report) closed the most recent trading day at $144.71, moving -1.91% from the previous trading session. This move lagged the S&P 500's daily loss of 0.59%. On the other hand, the Dow registered a loss of 0.6%, and the technology-centric Nasdaq decreased by 0.65%.
Prior to today's trading, shares of the pharmaceutical company had gained 10.99% outpaced the Medical sector's loss of 0.36% and the S&P 500's loss of 1.37%.
Market participants will be closely following the financial results of Merck in its upcoming release. In that report, analysts expect Merck to post earnings of $2.27 per share. This would mark a year-over-year decline of 12.02%. Meanwhile, the latest consensus estimate predicts the revenue to be $17.61 billion, indicating a 1.94% increase compared to the same quarter of the previous year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $2.97 per share and revenue of $67.25 billion. These totals would mark changes of -66.93% and +3.45%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Merck. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.38% lower. Merck is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Merck has a Forward P/E ratio of 49.6 right now. Its industry sports an average Forward P/E of 15.55, so one might conclude that Merck is trading at a premium comparatively.
Meanwhile, MRK's PEG ratio is currently 5.97. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry had an average PEG ratio of 2.01 as trading concluded yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 101, positioning it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRK in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Merck (MRK) Dips More Than Broader Market: What You Should Know
Merck (MRK - Free Report) closed the most recent trading day at $144.71, moving -1.91% from the previous trading session. This move lagged the S&P 500's daily loss of 0.59%. On the other hand, the Dow registered a loss of 0.6%, and the technology-centric Nasdaq decreased by 0.65%.
Prior to today's trading, shares of the pharmaceutical company had gained 10.99% outpaced the Medical sector's loss of 0.36% and the S&P 500's loss of 1.37%.
Market participants will be closely following the financial results of Merck in its upcoming release. In that report, analysts expect Merck to post earnings of $2.27 per share. This would mark a year-over-year decline of 12.02%. Meanwhile, the latest consensus estimate predicts the revenue to be $17.61 billion, indicating a 1.94% increase compared to the same quarter of the previous year.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $2.97 per share and revenue of $67.25 billion. These totals would mark changes of -66.93% and +3.45%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Merck. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.38% lower. Merck is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that Merck has a Forward P/E ratio of 49.6 right now. Its industry sports an average Forward P/E of 15.55, so one might conclude that Merck is trading at a premium comparatively.
Meanwhile, MRK's PEG ratio is currently 5.97. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals industry had an average PEG ratio of 2.01 as trading concluded yesterday.
The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 101, positioning it in the top 42% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRK in the coming trading sessions, be sure to utilize Zacks.com.